z-logo
open-access-imgOpen Access
Prostate Apoptosis Response-4 Involved in the Protective Effect of Salvianolic Acid B Against Amyloid β Peptide-Induced Damage in PC12 Cells
Author(s) -
Michelle Tang,
Juntian Zhang
Publication year - 2002
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.88.422
Subject(s) - apoptosis , cytotoxicity , flow cytometry , mtt assay , microbiology and biotechnology , chemistry , cytotoxic t cell , amyloid beta , peptide , toxicity , western blot , beta (programming language) , in vitro , biochemistry , biology , organic chemistry , gene , computer science , programming language
To observe the effect of salvianolic acid-B (SalB) against the cytoxicity of amyloid beta peptide (A-beta)(25-35) to PC12 cells, the cells were incubated with A-beta, and the cytoxicity was investigated by MTT, flow cytometry and a cell free apoptotic system. The expression of prostate apoptotic response-4 (Par-4) was detected by Western blot. Aged A-beta 10 micromol/L significantly inhibited the MTT reduction of PC12 cells, SalB1 micromol/L inhibited the toxicity induced by A-beta. In flow cytometric analysis, PC12 cells treated with A-beta exhibited degraded DNA content characteristic of apoptosis cells (1.53% vs 19.9%). PC12 cells pretreated with SalB (10 nmol/L, 100 nmol/L, 1 micromol/L) manifested relatively low proportion of apoptosis (15.7%, 13.5%, 11.8%, respectively). SalB (10 nmol/L - 1 micromol/L) when added at the beginning of the cell free apoptotic reaction had no apparent effect on the nuclei apoptosis. Pretreatment of PC12 cells with SalB largely prevented the increase in Par-4 expression of the cells when they were exposed to A-beta. The results suggest that Par-4 is involved in the protective effect of SalB against A-beta-induced damage in PC12 cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here